Melanoma, KIT-mutated

Back to Top
Note: these are regimens tested in biomarker-specific populations, please see the main melanoma page for other regimens.
Last updated on 2024-07-23:2 regimens on this page
3 variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==NCCN==
*NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Melanoma: Cutaneous.
=Advanced or metastatic disease, TKI-naive=
==Imatinib monotherapy==
===Regimen variant #1, pre-planned escalation===
Study 	Dates of enrollment	Evidence
Hodi et al. 2013 (BUS255)	2006-2011 	Phase 2
Note: upon progression, the dose of imatinib was escalated; see below.
====Biomarker eligibility criteria====
*Gene: KIT
*Alteration: amplification and mutation
*Acceptable methods of measurement: PCR or HPLC
====Targeted therapy====
*Imatinib (Gleevec) 400 mg PO once per day
Continued indefinitely (see note)
===Regimen variant #2===
Study 	Dates of enrollment	Evidence
Carvajal et al. 2011 (MSKCC 07-014)	2007-2010 	Phase 2
Patients had melanomas arising from mucosal, acral, and chronically sun-damaged skin with KIT mutations or amplifications.
====Biomarker eligibility criteria====
*Gene: KIT
*Alteration: amplification or mutation
====Targeted therapy====
*Imatinib (Gleevec) 400 mg PO twice per day on days 1 to 42
42-day cycles
===References===
#MSKCC 07-014: Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Jun 8;305(22):2327-34. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT00470470
#BUS255: Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. J Clin Oncol. 2013 Sep 10;31(26):3182-90. Epub 2013 Jun 17. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT00424515
=Advanced or metastatic disease, TKI-exposed=
==Imatinib monotherapy==
===Regimen variant #1, pre-planned escalation===
Study 	Dates of enrollment	Evidence
Hodi et al. 2013 (BUS255)	2006-2011 	Phase 2
====Biomarker eligibility criteria====
*Gene: KIT
*Alteration: amplification and mutation
*Acceptable methods of measurement: PCR or HPLC
====Prior treatment criteria====
*Imatinib 400 mg/day, with progression
====Targeted therapy====
*Imatinib (Gleevec) 400 mg PO twice per day
Continued indefinitely
===References===
#BUS255: Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. J Clin Oncol. 2013 Sep 10;31(26):3182-90. Epub 2013 Jun 17. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT00424515
Category:Melanoma regimens
Category:Biomarker-specific pages
Category:Skin cancers